Company Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases.
Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease.
Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer.
The company was incorporated in 2004 and is headquartered in New York, New York.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 40 |
CEO | Dr. Christopher U. Missling M.B.A., M.S., Ph.D. |
Contact Details
Address: 630 5th Avenue, 20th Floor New York, New York 10111 United States | |
Phone | 844-689-3939 |
Website | anavex.com |
Stock Details
Ticker Symbol | AVXL |
Exchange | NASDAQ |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0001314052 |
CUSIP Number | 032797300 |
ISIN Number | US0327973006 |
Employer ID | 98-0608404 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary and Director |
Sandra Boenisch CPA, CGA | Principal Financial Officer and Treasurer |
Stephan Toutain M.B.A., M.S. | Senior Vice President of Operations and Chief Operating Officer |
Dr. Walter E. Kaufmann M.D. | Chief Scientific Officer |
Clint Tomlinson | Vice President of Corporate |
Dr. Adebayo Laniyonu Ph.D. | Senior Vice President of Nonclinical Development |
Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer |
Dr. Kun Jin Ph.D. | Head of Biostatistics |
David Goldberger R.Ph. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | 144 | Filing |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 7, 2024 | 10-Q | Quarterly Report |
Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 27, 2023 | 10-K | Annual Report |
Aug 8, 2023 | 10-Q | Quarterly Report |
Jun 28, 2023 | 144 | Filing |
May 24, 2023 | 8-K | Current Report |
May 9, 2023 | 10-Q | Quarterly Report |